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A common characteristic of axonopathy is the abnormal accumulation of cytoskeletal
proteins. We recently reported that streptozotocin (STZ)-induced type 1 diabetes produced
a change in the morphology of sympathetic nerve fibers supplying rat plantar metatarsal
arteries (PMAs). Here we investigated whether these morphological changes are
associated with axonal accumulation of the type III intermediate filament peripherin
and the microtubule protein β-tubulin III, as both are implicated in axonal remodeling.
PMAs from hyperglycemic STZ-treated rats receiving a low dose of insulin (STZ-LI) were
compared with those from normoglycemic STZ-treated rats receiving a high dose of
insulin (STZ-HI) and vehicle-treated controls. Western blotting revealed an increase in
protein expression level for peripherin in PMAs from STZ-LI rats but no change in that for
β-tubulin III. In addition, there was an increase in the number of peripherin immunoreactive
nerve fibers in the perivascular nerve plexus of PMAs from STZ-LI rats. Co-labeling for
peripherin and neuropeptide Y (a marker for sympathetic axons) revealed that peripherin
immunoreactivity increased in sympathetic axons. None of these changes were detected
in PMAs from STZ-HI rats, indicating that increased peripherin in sympathetic axons of
STZ-LI rats is likely due to hyperglycemia and provides a marker of diabetes-induced nerve
damage.
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INTRODUCTION
Recently we demonstrated impaired sympathetic neurovascular
transmission in plantar metatarsal arteries (PMAs) from rats with
streptozotocin (STZ)-induced diabetes, a well-studied model of
type I diabetes (Johansen et al., 2013). In PMAs from STZ-treated
rats that received no insulin, the reduction in nerve-evoked
vasoconstriction was associated with a decrease in perivascular
nerve fiber density. By contrast, in PMAs from hyperglycemic
STZ-treated rats that received a low dose of insulin (i.e., a
dose insufficient to affect systemic glycemia), neither neurovas-
cular transmission nor perivascular nerve fiber density were
changed. However, in both groups of hyperglycemic STZ-treated
rats, the PMA perivascular nerve fibers were similarly thickened
and had increased tyrosine hydroxylase (TH) immunoreactivity.
Therefore, it is possible that diabetes produces changes to the
sympathetic innervation of PMAs before functional changes can
be detected. For this reason it is important to identify diabetes-
induced changes to the perivascular sympathetic nerves that
precede disruption of neurovascular function.
In both animals and humans, present evidence indicates that
diabetes does not cause significant loss of sympathetic neurons
(Schmidt, 2002). Microscopic studies of perivascular axons in
mesenteric and tail arteries from rats with STZ-induced dia-
betes have not revealed any structural changes (Schmidt et al.,
1988; Belai et al., 1996; Speirs et al., 2006; Johansen et al., 2013).
Therefore, the sympathetic neurons supplying the PMAs appear
to be selectively vulnerable to the effects of type 1 diabetes. It
has been reported that STZ-induced diabetes produces swelling
of sympathetic axons supplying the intestine, corpus cavernosum
and pineal gland (Schmidt et al., 1981; Morrison et al., 2007;
Tsai et al., 2008). In mesenteric nerves supplying the distal ileum
and colon of diabetic rats, Schmidt et al. (Schmidt et al., 1981,
1988; Schmidt and Scharp, 1982; Clark and Schmidt, 1984) have
described both degenerating and regenerating sympathetic axons.
Indeed the number of axons in the mesenteric nerves increased,
suggesting that diabetes stimulates axon sprouting (Schmidt and
Scharp, 1982). A increase in sympathetic nerve terminal density
has also been reported in the heart of rats with STZ-induced
diabetes (Felten et al., 1982).
Therefore, we hypothesized that nerve fiber thickening in
perivascular nerve plexus of PMAmight be due to both abnormal
increases in axon diameter and sprouting of sympathetic axons
within the nerve fibers. In sympathetic ganglia, diabetes-induced
increases in axon diameter were associated with the accumula-
tion of the type III intermediate filament peripherin (Schmidt
et al., 1997), which has recently been demonstrated to be a nor-
mal subunit of neurofilaments in peripheral neurons (Yuan et al.,
2012). This finding accords with the demonstration that axonal
caliber is proportional to the number of neurofilaments (see
Holmgren et al., 2012). Therefore, to assess if diabetes might be
having a similar effect on sympathetic nerves supplying PMAs, we
assessed if there were increases in immunolabeling for peripherin.
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In addition, we assessed if diabetes increased immunolabeling
for the neuron specific neurotubule protein β-tubulin III, which
is an axon growth associated tubulin that is upregulated during
regeneration of peripheral axons and incorporated into the neu-
rotubules in newly grown axons (Moskowitz and Oblinger, 1995;
Hoffman, 2010). This pan axonal marker also allowed us to assess
changes to the entire perivascular nerve plexus. We also used
Western blots to assess if diabetes increased protein expression
levels for peripherin and β-tubulin III in the whole tissue.
MATERIALS AND METHODS
ANIMAL HANDLING AND TISSUES
All experiments were approved by the University of Melbourne
Animal Ethics Committee and conformed to the Australian code
of practice for the care and use of animals for scientific purposes.
Male Wistar rats, 8–10 weeks old, from the Animal Resources
Centre (Canning Vale, WA, Australia), were treated intraperi-
toneally with 60mg/kg STZ (Sigma-Aldrich Pty. Ltd., Sydney,
NSW, Australia) dissolved in 50mM citrate buffer (pH 4.5). Age-
matched vehicle control animals were treated with an equivalent
volume of citrate buffer. Blood glucose levels were measured 5–7
days post-injection using a glucose meter (Accu-Check Performa,
Roche Diagnostics Australia Pty Ltd) to confirm that the STZ-
treated rats were diabetic (>15mM glucose). The STZ-treated
rats were then divided into two groups, one of which received
a low dose of insulin and were hyperglycemic (STZ-LI; blood
glucose >15mM) and the other received a high dose of insulin
and were normoglycemic (STZ-HI; blood glucose <15mM).
Insulin was delivered by sustained-release implants (Linplant,
Linshin Canada Inc.) inserted subcutaneously beneath the nuchal
skin. The STZ-LI rats received half a Linplant pellet (∼1 insulin
unit/day) at 1 week and again at 6–7 weeks post-STZ treatment.
The first cohort of STZ-HI rats received 2 Linplant pellets (∼4
insulin units/day) at 1 week and 6–7 weeks after STZ treatment.
To better maintain normoglycemic levels and prevent the animals
from becoming transiently hypoglycemic, the second cohort of
STZ-HI rats initially received 1.5 pellets at 1 week post-STZ treat-
ment and then received additional pellets (1–1.5 pellets) at ∼30
day intervals when the blood glucose levels increased to between
10 and 15mM. Blood glucose levels and body weights were mon-
itored at weekly intervals until rats were terminated 12–13 weeks
after the induction of diabetes. Animals were maintained on a
12:12 h light-dark cycle and were provided with food and water
ad libitum.
At termination the animals were deeply anesthetized with
isoflurane and exsanguinated by cutting the carotid arteries.
Approximately 1ml of blood was collected in EDTA tubes from
all rats to determine the glycosylated hemoglobin levels by high-
performance liquid chromatography (CLC330 GHb Analyzer,
Primus, Kansas City, MO). From each hind paw, themedian plan-
tar artery and the five PMAs branching from the plantar arch
were dissected in cold phosphate buffered saline (PBS) containing
1:1000 of 50mM protease inhibitor phenylmethylsulfonyl fluo-
ride (PMSF; Sigma-Aldrich). The first two PMAs from the medial
side of each hind paw were used for immunohistochemistry. The
remaining arteries from both hind paws were pooled for each
animal and snap frozen in liquid nitrogen and stored at −80◦C.
TISSUE SAMPLE PREPARATION FOR WESTERN BLOTS
The following solutions were added to each arterial tissue sam-
ple (wet weight ≤30 mg): 300μl RIPA buffer (Sigma-Aldrich),
3μl protease inhibitor cocktail (Sigma-Aldrich), 0.5μl of 50mM
PMSF. Samples were kept at 4◦C during the following proce-
dures. Arteries were diced using scissors, sonicated for 3–4 s twice
(speed 6; XL2000, Misonix, NY, USA), centrifuged at ∼18,000 g
for 5min, and then the supernatant was collected. As per man-
ufacturer’s instructions, the protein content of each sample was
quantified using Bio-Rad’s Dc™ Protein Assay Kit (Bio-Rad
Laboratories Pty., Ltd., Gladesville, NSW, Australia). Samples
were aliquoted in volumes required to load 20μg of protein per
well on the gels and stored at −80◦C.
WESTERN BLOTS
Proteins were separated using a Mini-PROTEAN 3
Electrophoresis System (Bio-Rad). To each sample, an equal
volume of Laemmli sample buffer (Bio-Rad) and 2μL of
2-mercaptoethanol (Sigma-Aldrich) per 50μL of sample was
added. Samples were heated to ∼100◦C for 5min and loaded into
the wells of Mini-PROTEAN® TGX™ precast 4–20% gradient
gels (Bio-Rad) immersed in Tris/glycine buffer (2.5mM Tris,
19.2mM glycine, pH 8.3). One well in each gel was loaded
with 6μl of molecular weight marker (Bio-Rad). To allow
comparisons between the protein content of samples run on
different gels, at least one well per gel contained a protein sample
common to all gels (internal standard). Proteins were separated
electrophoretically at 100V for 100min at room temperature.
After separation, the proteins were transferred to nitrocellulose
membranes (pore size 0.22μm; LI-COR, NE, USA) using a Mini
Trans-Blot® Electrophoretic Transfer Cell (Bio-Rad). Each tank
was filled with Tris/glycine buffer containing 20% (v/v) methanol
and transfers were carried out overnight at 30V and 4◦C. After
staining with ponceau red (Sigma-Aldrich) to confirm protein
transfer was successful, the membranes were washed 3× with
distilled water and air dried for 1 h at room temperature.
ANTIBODY LABELING FOR WESTERN BLOTS
Membranes were blocked in casein blocking buffer (LI-COR,
NE, USA) for 1 h at room temperature. Both, primary and sec-
ondary antibodies were diluted in casein buffer containing 0.01%
Tween-20 (Sigma-Aldrich). The membranes were incubated with
mouse anti-β-tubulin III (1:1000; Cat. No. MMS-435P, Covance,
Princeton, NJ, USA) or rabbit anti-peripherin (1:5000; Cat. No.
AB1530, Chemicon-Millipore-Merck, Kilsyth, VIC, Australia) at
4◦C overnight. Unbound antibodies were removed by washing
with PBS containing 0.001% Tween-20 (3 × 10min). Membranes
immunolabeled for peripherin were then incubated with fluores-
cent secondary antibody, IRDye® donkey anti-rabbit IgG 800CW
(1:1000; LI-COR) for 1 h at room temperature before they were
again washed with PBS-0.001% Tween-20 (3 × 10min) and then
with PBS alone (1 × 10min). β-tubulin III labeling was visualized
by applying a biotin-streptavidin step to enhance signal detec-
tion. Biotinylated horse anti-mouse IgG antibody (1:5000; Cat.
No. BA-2000, Vector Labs, Burlingame, CA, USA) was applied
for 1 h at room temperature and then the membrane was washed
with PBS-0.001% Tween-20 (3 × 10min). The membranes were
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then fluorescently labeled with streptavidin 680LT dye (1:20,000,
LI-COR) for 1 h at room temperature before being washed off
with PBS-0.001% Tween20 (3 × 10min) and then with PBS alone
(1 × 10min).
Membranes were imaged using LI-COR’s Odyssey® near
infrared imager and images were acquired using the program
Odyssey v2.1. After the protein of interest was imaged, the
membranes labeled with mouse anti-β-tubulin III or rabbit anti-
peripherin antibodies were co-labeled with antibodies against β-
actin raised in either rabbit (1:1000; Cat. No. 926-42210, LI-COR)
or mouse (1:10,000; Cat. No. 926-42212, LI-COR), respectively.
Membrane-bound β-actin antibodies were labeled with fluores-
cent IRDye® donkey anti-rabbit IgG 800CW (1:1000; Cat. No.
926-32213, LI-COR) or IRDye® donkey anti-mouse IgG 680LT
(1:5000; Cat. No. 926-68022, LI-COR). After β-actin labeling,
both the protein of interest and housekeeper protein were imaged
simultaneously.
The integrated fluorescence intensity of the bands was mea-
sured using ImageJ (NIH, Bethesda, USA). Expression level for
the protein of interest (i.e., β-tubulin III or peripherin) in each
sample was determined relative to that of β-actin. As reported in
the results, we confirmed that the protein content of the β-actin
bands did not differ among the samples from the control, STZ-HI
and STZ-LI groups of rats. To correct for inter-gel variability, the
relative values for the test samples on each gel were normalized to
that for the internal standard on the same gel.
TISSUE FIXATION AND IMMUNOHISTOCHEMISTRY
PMAs were fixed at their in vivo length in Zamboni’s fixative
overnight at 4◦C. Samples were washed with dimethyl sulfoxide
(3 × 10min) followed by PBS (3 × 10min), and stored in PBS
containing 0.01% (w/v) sodium azide at 4◦C. In all immunohis-
tochemical experiments, PMAs collected from STZ-treated and
control rats terminated on the same day were performed in
parallel on the same slide (i.e., for each set of immunolabels).
Tissues were blocked for 1 h in PBS containing1% (v/v) Triton
(Sigma-Aldrich) and 10% (v/v) normal horse serum. Tissues were
labeled in different combinations (presented in the results) with
the following primary antibodies: rabbit anti-peripherin (1:500),
mouse anti-β-tubulin III (1:750), sheep anti-neuropeptide Y
(NPY; 1:2000; Clone E2210, Gift from J. Oliver) and rabbit anti-
calcitonin gene-related peptide (CGRP; 1:1000; Cat. No. T-4032,
Bachem, Bubendorf, Switzerland). Primary antibodies were visu-
alized using fluorescent secondary antibodies raised in donkey
(Molecular Probes, Inc., OR, USA); anti-rabbit 488 (1:1000; Cat.
No. A21206), anti-mouse 647 (1:500; Cat. No. A31571), and/or
anti-sheep 647 (1:500; Cat. No. A21448). No primary antibody
controls were performed for each sample to ensure specificity
of secondary antibodies. Antibodies were diluted in antibody
diluent (290.9mM NaCl, 7.5mM Na2HPO4, 2.5mM NaH2PO4,
and 0.1% (w/v) sodium azide; pH 7.1). Tissues were incubated
with the primary antibody overnight at 4◦C. Excess antibody
was washed off with PBS (3 × 10min) and secondary antibod-
ies were applied for 1 h at room temperature. Samples were
then washed with PBS (3 × 10min) and mounted and cover-
slipped on Starfrost® slides (Waldemar Knittel Glasbearbeitungs
GmbH, Braunschweig, Germany) with fluorescence mounting
medium (Dako North America, Inc., CA, USA). Samples
were viewed with a Zeiss Pascal confocal microscope sys-
tem and imaged as Z-stacks through the entire adventitial
thickness.
DATA ANALYSIS
All statistical analyses were performed using SPSS 19 (IBM Corp,
Armonk, NY, USA) or GraphPad Prism (GraphPad Inc., La
Jolla, CA, USA). For Western blotting experiments and the mea-
surements of net body weight gain, % glycosylated hemoglobin
and blood glucose levels at termination, comparisons were first
made among control, STZ-HI and STZ-LI groups using One-
Way ANOVA or a Kruskal–Wallis test if the data variance dif-
fered significantly among the experimental groups (assessed using
Levene’s test). Post-hoc pairwise comparisons were made with
Tukey’s honest significant difference (HSD) tests or Dunn’s tests.
When parametric tests were used the data is expressed as means
and standard errors of the mean (SEM), whereas when non-
parametric tests were used the data are presented as medians and
interquartile ranges.
The β-tubulin III and peripherin immunolabeled perivascular
axon plexus innervating PMAs was quantified using maximum
intensity Z-projection images collected with a ×63 objective
(512 × 512 pixels, pixel size 0.24μm2). This was done by collect-
ing the pixel intensity values along two horizontal lines placed at
the same points on all images (one in the upper half and the other
in the lower half of the image) using the line profile function in
ImageJ (National Institute of Health, Bethesda,MD) (see Figure 2
for representative line profiles). After subtracting the mean max-
imum background pixel intensity value (determined from 10
points on the image where there was no detectable fluorescence),
the number and widths of the nerve fiber intercepts along the
line profiles (i.e., regions with pixel values >0) were determined
using an in-house routine composed in Igor Pro (Wavemetrics,
Lake Oswego, OR, USA). ImageJ was used to measure the per-
centage area of the vessel surface covered by the β-tubulin III
or peripherin immunoreactive (IR) nerve plexus and the inte-
grated peripherin and β-tubulin III-IR fluorescence per 100μm2
of vessel surface (for both of these measures the mean maxi-
mum background pixel intensity value was used as the threshold
for detecting nerve fibers). For each nerve plexus measure, one-
sample Student’s t-tests were used to determine if the measures
in arteries from STZ-treated animals expressed as a percentage
of those in the control tissues collected on the same day (and
processed in parallel) differed significantly from 100%. For each
animal, themeasures were the average obtained from at least three
image Z-stacks.
For studies assessing co-localization of peripherin-IR and
NPY-IR, horizontal pixel intensity line profiles for each label were
obtained at the same two points on each image (one in the upper
half and the other in the lower half of the image) as described
above (see Figure 6 for representative line profiles). Prior to
assessing co-localization, the mean maximum background pixel
intensity value for each label (determined as described above) was
subtracted from the line profile for that label. For each pair of
line profiles collected at the same point on the image, co-labeling
was assessed by determining the percentage of fluorescence peaks
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along each line profile at which the pixel value at the same location
on the other line profile was >0. This allowed us to determine
the percentage of peripherin-IR intercepts that were also NPY-
IR, and vice versa. Additionally, the integrated NPY-IR fluores-
cence per 100μm2 of vessel surface was measured (as described
above).
RESULTS
ANIMALS
All STZ-treated rats had elevated blood glucose levels (>20mM)
prior to insulin treatment (at 1 week after STZ treatment), and the
blood glucose levels for the STZ-LI rats was >15mM through-
out the 12 week period (Figure 1). In comparison, the blood
glucose levels of STZ-HI rats were greatly reduced by insulin treat-
ment (Figure 1; between STZ-LI and STZ-HI group comparison
P < 0.001). At termination, the blood glucose levels did not dif-
fer between control and STZ-HI rats, but both had levels that were
significantly lower than those for STZ-LI rats (Table 1). The net
body weight gain for STZ-LI animals at termination was less than
for both STZ-HI and control rats, and that for the STZ-HI rats
was also less than that for the controls (Table 1). Terminal % gly-
cosylated hemoglobin levels in blood from STZ-LI rats (∼16%)
were about twice those in STZ-HI rats (∼8%), but levels in STZ-
HI rats were slightly higher than those in control rats (∼5%)
(Table 1).
FIGURE 1 | Blood glucose levels (mM) measured at weekly intervals
after i.p. injection of streptozotocin (STZ). Before the insertion of insulin
pellets (at 1 week) all STZ-treated rats had elevated blood glucose levels.
Throughout the 12-week period, STZ-treated rats given a low dose of insulin
(STZ-LI, n = 22) maintained blood glucose levels >15mM (i.e.,
hyperglycemic). Those given a high dose of insulin (STZ-HI, n = 19), at 3
weeks and thereafter had blood glucose measurements <15mM. The
graph also shows blood glucose measurements at 1 week and at 12 weeks
in citrate buffer-treated control rats (n = 30) and these data points are
joined by the dashed line. The first arrow indicates the time at which the
STZ-LI and STZ-HI rats received their first insulin pellet(s). The second
arrow indicates the time the STZ-LI rats and the first cohort of STZ-HI rats
received their second insulin pellet(s). The other STZ-HI rats were given
additional insulin pellets when their blood glucose increased to between 10
and 15mM.
A SUBSET OF THE PERIVASCULAR AXONS INNERVATING THE PMAs
WAS PERIPHERIN-IR
Most, if not all, of the axons within the nerve plexus of PMAs
are β tubulin III-IR (Johansen et al., 2013). Figure 2 shows
images for PMAs from a control (Figures 2A–C) and a STZ-LI
rat (Figures 2E–G) immunolabeled for both β-tubulin III and
peripherin. Only the thicker β-tubulin III-IR nerve fibers were
strongly peripherin-IR in PMAs from control and STZ-HI rats
(not shown). By contrast, in the PMAs from the STZ-LI rats,
there was an increase in peripherin-IR in the finer nerve fibers
(c.f. Figures 2B,F). Figure 2 also shows representative line profiles
used for quantifying the β-tubulin III-IR and peripherin-IR nerve
plexus (see below) collected from the images (Figures 2D,H).
PMA β-ACTIN PROTEIN EXPRESSION LEVELS DID NOT VARY AMONG
TREATMENT GROUPS
The β-actin protein expression in all PMA samples was identified
as a 45 kDa band (Figures 3A,C). The intensity values relative to
the internal standard for β-actin protein expression for arteries
from each treatment group (i.e., controls, STZ-HI and STZ-LI)
were compared to ensure diabetes did not alter β-actin protein
content. Among the three groups, no differences in β-actin pro-
tein expression (Table 2) were detected. β-actin was therefore an
appropriate loading control for standardizing β-tubulin III and
peripherin protein expression for PMAs.
β-TUBULIN III CONTENT IN PMAs WAS NOT CHANGED BY DIABETES
Three bands were identified by streptavidin detection on the
Western blots for β-tubulin III (Figure 3A). The first two bands
(from the top) had much higher molecular weights (∼120
and ∼75 kDa) than that expected for β-tubulin III (∼50 kDa).
These bands were also present on the membranes where no
primary antibody or biotinylated antibody had been applied
and are therefore most likely due to streptavidin binding to
endogenous biotin or a biotin-like protein present in the samples
Table 1 | Net body weight gains, % glycosylated hemoglobin levels
and blood glucose levels at termination in streptozotocin
(STZ)-treated rats receiving a high (STZ-HI) or low (STZ-HI) dose of
insulin and their controls.
Groups Net body
weight
gain (g)
% Glycosylated
hemoglobin
Terminal blood
glucose level
(mM)
Control (n = 30) 241 ± 9 5.1 ± 0.4 6.0 (5.4–6.7)
STZ-HI (n = 19) 196 ± 9 7.7 ± 0.7 5.8 (4.7–8.5)
STZ-LI (n = 22) 104 ± 8 16.4 ± 0.5 26.1 (23.8–27.8)
Comparison between
groups
P < 0.001
F = 63.55
P < 0.001
F = 136.0
P < 0.001
Kruskal-Wallis
statistic = 45.05
Pairwise Control vs. STZ-HI P < 0.001 P < 0.001 P = 0.61
comparison Control vs. STZ-LI P < 0.001 P < 0.001 P < 0.001
STZ-HI vs. STZ-LI P < 0.001 P < 0.001 P < 0.001
Data are presented as means and s.e.m.’s or medians and interquartile ranges
(in parentheses). Comparisons between the control, STZ-HI, and STZ-LI groups
were initially made using One-Way ANOVA or the Kruskal-Wallis test and pair-
wise comparisons between the groups were made with Tukey’s HSD or Dunn’s
tests.
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FIGURE 2 | Images showing immunolabeling for β-tubulin III (magenta;
A,E) and peripherin (green; B,F) and the combination of both proteins
(C,G) in the perivascular nerve plexus of a plantar metatarsal artery
(PMA) from a control rat (A–C) and a streptozotocin (STZ)-treated rat
(E–G) that received a low dose of insulin (STZ-LI). In comparison with the
PMA from the control rat, the β-tubulin III-immunoreactive (IR) nerve fibers
were thickened in the PMA from the STZ-LI rat. In addition, there was an
increase in the number of fine peripherin-IR fibers in the PMA from the STZ-LI
rat. (D,H) show representative pixel intensity line profiles (only pixel intensity
values above the mean maximum background level are shown) for β-tubulin
III-IR (magenta) and peripherin-IR (green) collected along the orange lines
indicated on (A,E) and (B,F), respectively (the pixel intensity scale bar in D also
applies in H). The images were collected with a ×63 objective and the length
scale bar in (A) indicates 50μm and applies to all images and line profiles.
(McKay et al., 2008). The third band at ∼50 kDa was consistent
with the predicted molecular weight of β-tubulin III (Figure 3A).
There was no difference in β-tubulin III content between PMAs
from control, STZ-HI and STZ-LI rats (Kruskal–Wallis test, df =
34, P = 0.14; Figure 3B).
THE THICKNESS OF β-TUBULIN III IMMUNOREACTIVE NERVE FIBERS
AND THE AREA OF THE VESSEL SURFACE COVERED BY THESE FIBERS
WERE INCREASED IN PMAs FROM STZ-LI RATS
The percentage area of the vessel surface covered by the β-
tubulin III-IR nerve plexus and the integrated β-tubulin III-IR
immunofluorescence per 100μm2 of the vessel surface were sig-
nificantly larger (∼20 and ∼45%, respectively) in PMAs from
STZ-LI rats compared to their controls (Figure 4A). In PMAs
from STZ-LI rats, the frequency of the β-tubulin III-IR intercepts
along the line profiles did not differ significantly from those of
their controls but the widths of the intercepts were ∼30% larger
(Figure 4A). For the PMAs from STZ-HI animals, all measures of
the β-tubulin III-IR nerve plexus did not differ from those of their
controls (Figure 4B).
PERIPHERIN CONTENT WAS SIGNIFICANTLY INCREASED IN PMAs
FROM STZ-LI RATS
Western blots for peripherin had a single protein band located
at a position slightly greater than 50 kDa (Figure 3C) and this
is consistent with the predicted molecular weight for periph-
erin (57 kDa). There was a significant difference in the periph-
erin content among PMAs from control, STZ-HI, and STZ-LI
rats (Figure 3D; One-Way ANOVA; F = 4.73, df = 34, P =
0.02). Post-hoc comparisons using Tukey’s tests revealed that
the peripherin protein expression levels were increased in PMAs
from STZ-LI rats compared to both control (P = 0.04) and STZ-
HI (P = 0.02) rats. There was no significant difference between
the peripherin content of PMAs from control and STZ-HI rats
(P = 0.96).
THE DENSITY OF PERIPHERIN-IR NERVE FIBERS WAS INCREASED IN
PMAs FROM STZ-LI RATS
The percentage area of the vessel surface covered by the
peripherin-IR nerve plexus and the integrated peripherin-IR flu-
orescence per 100μm2 of the vessel surface were both increased
by ∼60% in PMAs from STZ-LI rats compared to their con-
trols (Figure 4C). Additionally, compared to PMAs from control
rats, there was an approximately 25% increase in the frequency
of peripherin-IR intercepts along the line profiles in PMAs from
STZ-LI rats (Figure 4C). The widths of the intercepts along the
line profiles were also increased (∼15%) in PMAs from STZ-LI
rats (Figure 4C). For PMAs from STZ-HI animals, all measures of
the peripherin-IR nerve plexus did not differ from those of their
controls (Figure 4D).
LABELING FOR PERIPHERIN WAS INCREASED IN NERVE FIBERS THAT
WERE CO-LABELED FOR NPY
The majority of axons within the perivascular nerve plexus of
PMAs were NPY-IR and, relative to controls (Figure 5A), there
was increased labeling for NPY-IR in the nerve fibers supply-
ing PMAs from STZ-LI rats (Figure 5D; % increase in integrated
NPY-IR 189 ± 35%. n = 8, one sample Student’s t-test P <
0.05). These NPY-IR fibers are almost certainly sympathetic nerve
fibers, as we have previously reported that the perivascular nerve
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FIGURE 3 | β-tubulin III and peripherin protein levels in plantar
metatarsal arteries (PMAs) from control rats (n = 13) and streptozotocin
(STZ)-treated rats that received a low (STZ-LI, n = 12) or a high (STZ-HI,
n = 12) dose of insulin. (A,C) Representative Western blots for β-tubulin III
(A) and peripherin (C) in PMAs from a control, a STZ-HI and a STZ-LI rat. The
predicted molecular weights (MW) for β-tubulin III, peripherin and β-actin
were approximately 50, 57, and 45 kDa, respectively. (B,D) Protein expression
for β-tubulin III (B) and peripherin (D) was measured relative to loading
control β-actin. In (B), the median and interquartile range are indicated
whereas in (D) the mean and s.e.m. are indicated. There were no detectable
differences in β-tubulin III protein expression levels between PMAs from
control, STZ-HI, and STZ-LI rats. Peripherin protein expression in PMAs from
STZ-LI rats was greater than that in PMAs from control and STZ-HI rats. Initial
comparisons between the groups were made using a One-Way ANOVA (in D)
or the Kruskal-Wallis test (in B). In (D), pairwise comparisons between the
groups were made with Tukey’s tests (ns = not significant; ∗P < 0.05).
Table 2 | Comparison of β-actin protein expression levels (relative to
the internal standard) in arterial samples from control rats and
streptozotocin (STZ)-treated rats receiving a high (STZ-HI) or low
dose of insulin (STZ-LI).
Control STZ-HI STZ-LI
PLANTAR METATARSAL ARTERIES
2.64 1.56 2.09
(1.51–3.70) (1.19–2.83) (1.77–5.23)
n = 13 n = 12 n = 12
Kruskal-Wallis Test P = 0.22
Kruskal-Wallis statistic = 3.07
Data are presented as medians and interquartile ranges (in parentheses).
Statistical comparisons between the control, STZ-HI, and STZ-LI groups were
made using the Kruskal Wallis test.
plexus of PMAs is comprised primarily of tyrosine-hydroxylase
(TH)-IR fibers, with only a small number of peptidergic pri-
mary afferent nerve fibers containing CGRP (Johansen et al.,
2013). Sciatic nerve injury (Wakisaka et al., 1991, 1992; Ohara
et al., 1994) has been reported to increase expression of NPY
in the cell bodies of sensory neurons in dorsal root ganglia
(DRG). The possibility that diabetes increased NPY expression
in the CGRP-IR perivascular nerve fibers can be excluded, as the
CGRP-IR fibers did not co-label for NPY-IR in PMAs from either
control or STZ-LI rats (Figures 5A–F). In addition, we have pre-
viously demonstrated that the density of CGRP-IR fibers in the
perivascular nerve plexus is not different between PMAs from
control and STZ-LI rats (Johansen et al., 2013). Importantly, dia-
betes increases labeling for TH-IR in the nerve plexus of PMAs
(Johansen et al., 2013). Therefore, increased labeling for both
NPY-IR and TH-IR in PMAs from STZ-LI rats may be associated
with the thickening of the perivascular sympathetic nerve fibers
observed in these vessels.
To determine whether the diabetes-induced increase in
peripherin-IR occurred in sympathetic nerve terminals, line pro-
files were used to determine the percentage of peripherin-IR inter-
cepts that were also NPY-IR (a sympathetic nerve marker), and
vice versa, in PMAs from control and STZ-LI rats. Figure 6 shows
images for PMAs from a control (Figures 6A–C) and a STZ-LI
rat (Figures 6E–G) immunolabeled for both peripherin and NPY,
and representative line profiles for peripherin-IR andNPY-IR col-
lected from these images (Figures 6D,H). In control PMAs, the
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FIGURE 4 | The percent area of the vessel surface covered by the
immunolabeled nerve plexus (% area), integrated
fluorescence/100μm2 of vessel surface (integrated fluorescence), and
the frequency and width of intercepts along line profiles of plantar
metatarsal arteries (PMAs) immunolabeled for β-tubulin III (A,B) and
peripherin (C,D) from streptozotocin (STZ)-treated rats that received a
low (STZ-LI; A,C) or a high (STZ-HI; B,D) dose of insulin. All these
measures are expressed as a percentage of those in paired control tissues
(i.e., terminated on the same day). Relative to the controls, the β-tubulin
III-immunoreactive (IR) and peripherin-IR nerve plexus of PMAs from
STZ-LI rats (n = 8) had increases in the % area, the integrated
fluorescence and the widths of the intercepts along the line profiles. In
addition, in PMAs from STZ-LI rats there was an increase in the frequency
of peripherin-IR intercepts along the line profiles. For PMAs from STZ-HI
rats (n = 9), none of the measures of the β-tubulin III-IR or peripherin-IR
nerve plexus differed from those of their paired controls. The data are
presented as mean and s.e.m. Statistical comparisons were made with
one-sample t-tests (∗P < 0.05, ∗∗P < 0.01).
larger diameter fibers that were peripherin-IR showed little or
no NPY-IR (the green fibers in the merged image; Figure 6C).
In comparison with controls, STZ-LI PMAs had an increase in
the number of fibers that were co-labeled for peripherin and NPY
(white fibers in the merged image; Figure 6G); expression of NPY
and peripherin increased in the thicker and finer nerve fibers,
respectively (Figures 6E–G). In PMAs from STZ-LI rats, the per-
centage of intercepts along the line profiles for NPY-IR that were
co-labeled for peripherin-IR was increased compared to that in
PMAs from control rats (Figure 7A). Similarly, the percentage of
peripherin-IR intercepts that were NPY-IR increased in these ves-
sels (Figure 7B). These findings indicate that peripherin protein
expression increased in NPY expressing (i.e., sympathetic) nerve
fibers.
DISCUSSION
This study shows that STZ-induced type I diabetes increased
both the thickness of perivascular nerve fibers and the expres-
sion of peripherin in the perivascular nerve plexus of PMAs. As
the increase in peripherin immunolabeling occurred in nerve
fibers that were also NPY-IR, they are sympathetic nerve ter-
minals. As no changes in structure of the perivascular nerve
plexus or in peripherin protein expression or immunolabeling
were observed in PMAs from STZ-HI rats, the effects observed in
PMAs from STZ-LI rats were likely due to hyperglycemia and/or
to the reduced neurotrophic action of insulin (Sima, 2008). While
there was an increase in the integrated immunofluorescence for
β-tubulin III in the perivascular plexus of PMAs from STZ-LI
rats, the expression levels for this protein assessed using Western
blots were not significantly changed by diabetes. As there was no
increase in nerve fiber intercept frequency along the line profiles
for β-tubulin III-IR (i.e., nerve fiber density) but the % area of
the vessel surface covered by the β-tubulin III-IR nerve plexus
increased in PMAs from STZ-LI rats (Figure 4), the increase in
integrated immunofluorescence is most readily explained by the
increase in neural tissue associated with nerve fiber thickening
rather than an increase in the relative expression level of β-tubulin
III in the whole tissue (i.e., measured relative to the total tissue
β-actin).
Peripherin is a type III intermediate filament protein that
is expressed in subpopulations of peripheral neurons (i.e., sen-
sory, autonomic, and somatic motor neurons) (Escurat et al.,
1990; Gorham et al., 1990). It can assemble into filaments by
itself or with the three neurofilament (NF) proteins NF-light,
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FIGURE 5 | Images displaying immunoreactivity (IR) for neuropeptide Y
(NPY)(magenta; A,D) and calcitonin gene-related peptide (CGRP) (green;
B,E) and the combination of both markers (C,F) in the perivascular nerve
plexus of a plantar metatarsal artery (PMA) from a control rat (A–C) and a
streptozotocin (STZ)-treated rat (D–F) that received a low dose of insulin
(STZ-LI). In both vessels, the majority of nerve fibers in the perivascular nerve
plexus were NPY-IR and only a few axons were CGRP-IR. In comparison with
the PMA from a control rat, immunofluorescence for NPY was increased in the
PMA from the STZ-LI rat. The images were collected with a ×63 objective and
the scale bar in (A) indicates 50μm and applies to all images.
FIGURE 6 | Images showing immunolabeling for peripherin (green;
A,E) and neuropeptide Y (NPY: magenta; B,F) and the combination
of both molecules (C,G) in the perivascular nerve plexus of a
plantar metatarsal artery (PMA) from a control rat (A–C) and a
streptozotocin (STZ)-treated rat (E–G) that received a low dose of
insulin (STZ-LI). In comparison with the PMA from a control rat, the
number of peripherin-IR fibers that were NPY-IR increased in the PMA
from the STZ-LI rat. In addition, there was an increase in the
thickness and immunofluorescence of the NPY-IR fibers in the PMA
from the STZ-LI rat. (D) and (H) show representative line pixel
intensity profiles (only pixel intensity values above the mean maximum
background level are shown) for peripherin-IR (green) and NPY-IR
(magenta) collected along the orange lines indicated on (A,E) and
(B,F), respectively (the pixel intensity scale bar in D also applies in H).
The images were collected with a ×63 objective and the length scale
bar in (A) indicates 50μm and applies to all images and line profiles.
Frontiers in Neuroscience | Autonomic Neuroscience May 2014 | Volume 8 | Article 99 | 8
Johansen et al. Peripherin in diabetic sympathetic neuropathy
FIGURE 7 | Percentage of nerve fibers that were co-labeled for
peripherin and neuropeptide Y (NPY) in the perivascular nerve plexus
of plantar metatarsal arteries (PMAs) from control rats (n = 8) and
streptozotocin (STZ)-treated rats that received a low dose of insulin
(STZ-LI, n = 8). In comparison with PMAs from control rats, those from
STZ-LI rats had an increase in the number of NPY-immunoreactive (IR)
intercepts along the line profiles that were peripherin-IR (A) and vice versa
(B). The data are presented as mean and s.e.m. Statistical comparisons
were made with unpaired t-tests (∗∗P < 0.01).
NF-medium, and NF-heavy (Parysek et al., 1991; Beaulieu et al.,
1999). While the exact function of peripherin in neurons is
unknown, recent evidence indicates it is a normal subunit of neu-
rofilaments (together with the three NF proteins) in peripheral
neurons (Yuan et al., 2012). In PMAs from control rats, periph-
erin was expressed in axons within the thicker preterminal nerve
fibers but was not detectable or weakly expressed in axons within
the finer nerve terminal fibers that were closer to the vascular
muscle surface (Figure 2B). Labeling for peripherin increased in
finer nerve fibers of PMAs from STZ-LI rats (Figure 2F). As the
average width of the peripherin IR intercepts along the line pro-
files also increased in PMAs from STZ-LI rats, these findings are
consistent with an increase in axonal content of neurofilaments
causing an increase in axon diameter (see Holmgren et al., 2012).
The findings for β-tubulin III indicate that there was an
increase in neural tissue within the perivascular nerve plexus.
However, whether this effect of STZ-induced diabetes involves
an increase in the number of axons within the nerve fibers was
not resolved. Other studies have indicated that STZ-induced dia-
betes stimulates growth of sympathetic nerve terminals in the
heart (Felten et al., 1982), corpus cavernosum (Morrison et al.,
2007), and seminal vesicle (Morrison et al., 2006). In both corpus
cavernosum and seminal vesicle, the TH-IR of the nerve fibers
was increased (Morrison et al., 2006, 2007). In addition, STZ-
induced diabetes increased the NPY content of both the corpus
cavernosum and seminal vesicle (Morrison et al., 2009). We have
previously reported increased TH-IR of the perivascular nerve
fibers in PMAs from STZ-LI rats (Johansen et al., 2013) and the
present study demonstrated an increase in NPY-IR. Therefore, it
appears that the changes occurring in perivascular nerve plexus
of PMAs are similar to those occurring in other sympathetically
innervated tissues.
Current evidence indicates that sympathetic nerve terminals
normally undergo continuous cycles of degeneration and regen-
eration (i.e., they are continuously being remodeled) and that
this process may be exaggerated by diabetes (Schmidt, 2002).
Furthermore, it has been suggested that axonal structural changes
produced by diabetes are the result of initial nerve damage fol-
lowed by abnormal regeneration (Schmidt, 2002). In the longer
term, the loss of sympathetic axons that is believed to occur
in diabetic humans may be explained by the eventual failure of
damaged axons to regenerate (Sima, 2003; Yasuda et al., 2003).
Sympathetic neurons express insulin receptors raising the pos-
sibility that insulin has a direct trophic influence on these neurons
(James et al., 1993; Karagiannis et al., 1997). Previously we
reported that the low dose of insulin used in this study pre-
vented the reduction in both perivascular nerve fiber density
and neurovascular transmission observed in STZ-treated rats that
did not receive insulin support (Johansen et al., 2013). These
findings clearly suggest that these more substantive changes are
caused by the loss of insulin signaling rather than hyperglycemia.
While in the present study the protective actions of insulin were
observed with a dose that greatly reduced blood glucose levels,
we cannot exclude possibility that the changes to the perivascular
sympathetic nerve plexus axons observed in STZ-LI rats are also
produced by the reduced trophic influence of insulin on sympa-
thetic neurons. Indeed, reduced trophic support from insulin (or
insulin growth factor-1) has been suggested be the major deter-
minant of structural changes to sympathetic neurons supplying
the intestine of STZ-treated rats (Schmidt et al., 2003).
The changes in the perivascular nerve plexus of STZ-LI rats
were not associated with changes in neurovascular function
(Johansen et al., 2013). Indeed, in PMAs from STZ-treated rats
that did not receive any insulin, it is not possible to firmly con-
clude that the decrease in neurovascular transmission is explained
by the observed decrease in nerve fiber density, as vascular reac-
tivity to exogenously applied α-adrenoceptor agonists was also
decreased (Johansen et al., 2013). This indicates that the reduc-
tion in neurovascular transmission can be attributed, at least
partially, to a postjunctional change. Rarely have the effects of
changes to the perivascular vascular innervation on neurovascular
transmission been studied. Importantly, recent studies using sur-
gical lesions have demonstrated in rat tail artery that changes in
nerve-evoked contractions were only detected when greater than
50% of the perivascular nerves were removed (Tripovic et al.,
2013). Similarly, during reinnervation of denervated tail arter-
ies, neurovascular function returned to control levels when the
perivascular nerve density was less than control values (Tripovic
et al., 2011). These findings suggest there can be substantial
changes to the perivascular sympathetic innervation without
measurable changes in nerve-evoked contractions.
To our knowledge other microscopic studies of sympathetic
nerves supplying arterial vessels from rats with STZ-induced dia-
betes have not detected changes in nerve fiber structure, even with
durations of diabetes in excess of 1 year (Schmidt et al., 1988).
This suggests vasoconstrictor neurons supplying the planter vas-
cular bed are particularly vulnerable to the effects of diabetes,
as also appears to be the case in diabetic humans (Shore et al.,
1994; Cacciatori et al., 1997). In humans, we can find no reports
of changes to the perivascular nerve plexus of blood vessels pro-
duced by diabetes. However, long-term type 1 and type 2 diabetic
patients with neuropathic pain in their feet had reductions in
both norepinephrine release and the uptake of the sympathoneu-
ral imaging agent 6-[18F]fluorodopamine (imaged by positron
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emission tomography) in their feet (Tack et al., 2002). These
findings suggest that long-term diabetes can produce partial sym-
pathetic denervation of the feet. Importantly, none of the diabetic
patients studied by Tack et al. (2002) displayed characteristic signs
of diabetic sympathetic neuropathy (i.e., no orthostatic hypoten-
sion, normal blood pressure responses to the Valsalva maneuver,
and normal increments in plasma norepinephrine levels during
standing), consistent with the preferential vulnerability of sym-
pathetic neurons supplying the feet to the neurotoxic effects of
diabetes. This increased vulnerability may result from the long
axon length of the vasoconstrictor neurons supplying the feet,
as has been described for somatic sensory and motor neurons
(Anand et al., 1996). Therefore, it is possible that the effects of
STZ-induced diabetes on the sympathetic innervation of PMAs
with 12 weeks of STZ-induced diabetes represent early changes
that will lead to nerve fiber loss in the longer term.
The question remains whether similar changes to those we
have described in STZ-treated rats also occur in humans with
type 1 diabetes. While there appears to be no direct investiga-
tions of perivascular sympathetic nerves in human diabetics, there
are reports of increased, rather than decreased, sympathetic vaso-
motor regulation in young type 1 diabetics (e.g., Dalla Pozza
et al., 2007; Lucini et al., 2009). In addition, a number of stud-
ies have reported that reductions in parasympathetic control of
the heart in type 1 diabetic patients precede impairment of sym-
pathetic vasomotor regulation (e.g., Javorka et al., 2005; Dalla
Pozza et al., 2007). These findings suggest vasoconstrictor sym-
pathetic neurons are less vulnerable to the neurotoxic effects of
Type 1 diabetes. In plantar skin of patients with type 1 diabetes
for less than 3 years, there were increases in vasoactive intestinal
peptide (VIP) IR nerve fibers surrounding sweat glands, indicat-
ing increased cholinergic sympathetic innervation (Properzi et al.,
1993). With longer durations of diabetes, the numbers of VIP-
IR fibers surrounding sweat glands were significantly reduced. A
similar increase in the VIP-IR nerve fibers in the vicinity of sweat
glands has been demonstrated in skin from rats with 12 weeks of
STZ-induced diabetes (Karanth et al., 1990). These findings sug-
gest that type 1 diabetes initially induces growth of cholinergic
sympathetic neurons and that the changes seen at the 12 week
time point in STZ-treated rats are similar to those observed in
the initial stages of neuropathy in humans with type 1 diabetes.
However, whether type 1 diabetes stimulates growth of perivas-
cular noradrenergic sympathetic neurons at initial stages of type
1 diabetes in humans remains to be determined.
It is concluded that there are changes to the sympathetic
innervation of the PMAs before there are changes in neurovas-
cular function. It is possible that the changes observed in the
present study are related to the remodeling and regrowth of
sympathetic nerve endings damaged early in this model of dia-
betes, as has been suggested in the intestine (Schmidt, 2002).
Furthermore, as these changes were not observed in STZ-HI
rats, they might be induced by hyperglycemia-induced nerve
damage and/or reduced trophic support from insulin. The find-
ings suggest that changes in peripherin within the perivascular
nerve plexus may provide an early indication of diabetes induced
changes in perivascular nerves. In addition, they highlight the
possibility that early interventions will be needed to prevent the
onset of diabetes-induced changes in sympathetic neurovascular
transmission.
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